testing was due to the lengthening of the test interval when cotesting results were negative. Practitioners adhering to guidelines accounts for increased molecular testing volume. A trend towards higher-grade cervical intraepithelial neoplasia in the follow-up of detected HPV 16/18 was noted. So far there has been no demand for HPV as a stand-alone test.
Introduction
Over time, cervical cancer screening has evolved from a single glass slide smear to a test involving liquid-based processing and molecular HPV testing in the residual material.
Since 1988 the Bethesda System for reporting cervical/ vaginal cytology introduced the atypical squamous cells of undetermined significance (ASCUS) category under epithelial squamous cell abnormality [1] . It was noted, however, by the editors of the 1994 monograph [2] that cervical/vaginal cytopathology includes an element of subjective interpretation and consequently the application of criteria should be viewed within this context. Nu-merous clinicians were unhappy with the growing number of ASCUS interpretations issued by cytology laboratories. In 2001 the America Society for Colposcopy and Cervical Pathology (ASCCP) issued guidelines for human papillomavirus (HPV) testing [3] , and reflex HPV testing was recommended for cases interpreted as ASCUS in patients >20 years of age. When high-risk (HR) HPV was positive, the patient was referred to colposcopy and, when negative, returned to routine screening.
The use of HPV cotesting was approved as a cervical cancer screening test in the USA in 2003 and endorsed by the American Cancer Society (ACS) [4] . It was approved in combination with Papanicolaou (Pap) testing, for women 30 years or older every 3-5 years, but it was not approved as a stand-alone test.
Updated consensus guidelines from the ACS, ASCCP and American Society for Clinical Pathology were issued in 2012 [5] . The purpose of this retrospective review on Pap testing was to assess whether the cytology practice in our institution was affected by the introduction of HR HPV assays over time.
Materials and Methods
With institutional review board approval, we retrospectively reviewed cytology, HPV and histopathology records from our laboratory information system from 2003 to 2015. These records were obtained in collaboration with the pathology informatics director (R.S. Table 1 
Results

Discussion
In the last decade it has become clear that infection with HR HPV is required for the development of most cervical cancers and high-grade precursor lesions. Recent emphasis on molecular testing seeks to identify infection with HPV strains considered a high risk for carcinogenesis.
The clinical use of HPV testing started as additional screening for patients with ASCUS cervical cytology results in order to determine the need for colposcopy [3] . In our hospital practice, HR HPV reflex tests, automatically ordered by the cytology laboratory for ASCUS results, were performed from 2006 (when covered by insurance) and continue through the present.
In women 30 years and older, the HR HPV assay can be used in combination with cervical cytology to adjunctively screen for the presence or absence of HR HPV types. This information, together with the physician's assessment of the cytology history, other risk factors, and professional guidelines [5] , may be used to guide patient management. Table 1 shows that HPV cotesting at Thomas Jefferson University Hospital started in 2007 and progressively increased from 44 to 90% by 2015. At the same time, the decrease in Pap testing is striking from 11,792 in 2008 when the percentage of HPV testing was 19%, to 4,664 in 2015 with 59% utilizing HPV testing. It is known that a negative HR HPV test represents a low risk of developing disease over 5 years and safely allows lengthening of the test interval. This rationale is reasonable to explain our observed decrease in Pap testing. Also noticeable is the percentage decrease in HPV reflex testing and increase in HPV cotesting. Most likely this was the result of increased adherence by practitioners to cotesting guidelines [5] .
Of interest is the similar HR HPV detection rate in both reflex (32, 34, 27%) and cotests (12, 10, 10%) for the 3 HPV assays, as shown in The lack of demand for HR HPV stand-alone testing in our institution is of interest. Major changes to screening guidelines in the last decade include initiation of screening at the age of 21 years, conservative management of young women with abnormal cytology, extended screening intervals for women aged ≥ 30 years and cessation of screening in low-risk women over the age of 65 years [5] . HR HPV is a prerequisite for the development of almost all types of cervical cancer, therefore HR HPV has become an integral part of new screening strategies. With the FDA approval of the first HPV test for primary cervical cancer screening of women ≥ 25 years [6] , clinicians in the USA now have 3 different first-line screening options that they may offer to patients: the Pap test, cotesting with Pap and HPV, and HPV testing as a stand-alone test [7] . The choice of the cervical screening method may vary for a variety of reasons including patient and provider preference along with geographic, socioeconomic, and practice settings.
Conclusions
It is evident in our practice that ThinPrep Pap testing decreased from 11,792 to 4,664 (60%) over 8 years, while the percentage of HPV molecular testing (reflex plus cotesting) increased from 19 to 59%. The decrease in Pap testing is most likely due to an increased interval between tests when cotesting results were negative. The HPV detection rates assessed during a 3-month interval showed that the 3 HR HPV assays used, namely HC 2 ® , Cervista ® , and Cobas ® , detected similar rates of HR HPV. A trend was noted towards higher-grade CIN in the followup of HPV 16/18 detected cases. So far, the choices of the cervical screening method in our practice include the Pap test, HR HPV reflex test and cotesting with no demand for the HPV stand-alone test.
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